Lexeo Therapeutics Inc. C... (LXEO)
NASDAQ: LXEO
· Real-Time Price · USD
4.50
-0.29 (-6.05%)
At close: Aug 15, 2025, 10:06 AM
-6.05% (1D)
| Bid | 4.35 |
| Market Cap | 149.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -109.31M |
| EPS (ttm) | -3.31 |
| PE Ratio (ttm) | -1.36 |
| Forward PE | -2.33 |
| Analyst | Buy |
| Ask | 4.64 |
| Volume | 169,587 |
| Avg. Volume (20D) | 559,885 |
| Open | 4.91 |
| Previous Close | 4.79 |
| Day's Range | 4.49 - 4.95 |
| 52-Week Range | 1.45 - 12.76 |
| Beta | 1.36 |
About LXEO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LXEO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LXEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+50.92%
Lexeo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
-0.65%
Lexeo Therapeutics shares are trading higher. Leerink Partners maintained an Outperform rating on the stock.
3 months ago · seekingalpha.com
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program AdvancementLexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO regi...